Core F: Biomarker Core

核心 F：生物标志物核心

• 批准号: 10473830
• 负责人: Nicholas M Kanaan
• 金额: $ 35.38万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10473830
• 关键词: Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Amyloid beta-42; Amyloid beta-Protein; Antibodies; Automobile Driving; Biological Assay; Biological Markers; Blood; Brain; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collection; Coupled; Data; Databases; Dementia; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Educational Activities; Enzyme-Linked Immunosorbent Assay; Ethnic group; Evaluation; Faculty; Future; Goals; Health Professional; Interleukin-10; Interleukin-6; Light; Longitudinal cohort; Magnetic Resonance Imaging; Mass Spectrum Analysis; Measurement; Measures; Michigan; Modality; Molecular Profiling; Neuropsychology; Onset of illness; Patient Recruitments; Patients; Peripheral; Physicians; Plasma; Positron-Emission Tomography; Proteomics; Reagent; Research; Research Personnel; Research Support; Resources; Sampling; Scientist; Shapes; Students; System; TNF gene; Technology; Time; Translational Research; Universities; base; blood-based biomarker; cardiovascular risk factor; clinical center; clinical practice; cost; data management; diagnostic accuracy; disease heterogeneity; education research; genomic data; health training; innovation; neurofilament; neuroimaging; neuropathology; novel; novel marker; patient population; precision medicine; racial and ethnic; single molecule; targeted biomarker; tau Proteins

ABSTRACT – CORE F: BIOMARKER CORE Biomarkers are becoming instrumental components of effective clinical management and trial coordination for Alzheimer’s disease and related dementias (ADRD), and will be required to enable precision medicine approaches to diagnosis and treatment. The primary functions of the newly added Biomarker Core (BC) of the Michigan Alzheimer’s Disease Research Center (MADRC) will be to facilitate innovative research into established and novel blood biomarkers, and provide expertise and access to biomarker assay technologies for investigators at the University of Michigan, Michigan State University, Wayne State University, as well as other ADRCs. The overall goal of the BC is to use cutting-edge ultrasensitive ELISA and quantitative mass spectrometry (MS) approaches to measure biomarkers in blood, identify and build novel blood-based biomarker assays, and integrate biomarkers with clinical measures of disease. We will leverage MADRC resources from ongoing and future efforts to achieve this goal and promote studies that align with the MADRC’s central theme to identify, understand and modulate the many factors beyond β-amyloid contributing to ADRD. The diverse patient population in the MADRC’s longitudinal cohort and other ongoing clinical research efforts, coupled with the ability to develop novel biomarker assays, will significantly enhance the ability of the BC to focus on unique questions regarding the extent to which current and novel biomarker targets enhance diagnostic accuracy, and track disease progression and predictability over time in multiple patient populations, including underrepresented racial/ethnic groups. The BC will pursue the following five aims: 1) provide measurements of established blood biomarkers, 2) develop and implement novel biomarker assays, 3) facilitate integration of blood biomarkers with established clinical practices to advance translational research, 4) contribute blood biomarker data to the National Alzheimer’s Coordinating Center, and 5) educate and train health care professionals, scientists and students in the use of biomarker assays. The BC goals and aims will be achieved by working closely with the MADRC Clinical Core, Data Management and Statistical Core, Neuroimaging Core, Neuropathology Core, and Research Education Component. Through these efforts, the BC will markedly enhance research supported by the MADRC, leading to a sustained and significant impact for the field as we build a comprehensive assessment of the diagnostic and the predictive utility of blood-based biomarker profiles. We will also interface with other ADRCs and investigators to help shape an evolving clinical landscape for dementia evaluation and treatment.

摘要 – 核心 F：生物标志物核心 生物标志物正在成为有效临床管理和试验协调的重要组成部分 阿尔茨海默病和相关痴呆症 (ADRD)，将需要实现精准医疗 诊断和治疗方法的新添加的生物标记核心（BC）的主要功能。 密歇根阿尔茨海默病研究中心 (MADRC) 将促进以下方面的创新研究 已建立的新型血液生物标志物，并提供专业知识和生物标志物检测技术 密歇根大学、密歇根州立大学、韦恩州立大学以及 其他 ADRC 的总体目标是使用尖端的超灵敏 ELISA 和定量质量。 光谱分析 (MS) 方法可测量血液中的生物标志物，识别并构建新型血液生物标志物 我们将利用 MADRC 进行生物标志物测定，并将生物标志物与疾病的临床测量相结合。 为实现这一目标而进行的和未来的努力提供的资源，并促进与 MADRC 的中心主题是识别、理解和调节 β-淀粉样蛋白以外的许多因素 ADRD 的纵向队列和其他正在进行的临床中的不同患者群体。 研究，加上开发新型生物标志物检测的能力，将显着增强 BC 有能力关注有关当前和新型生物标志物的程度的独特问题 目标提高诊断准确性，并在多个时间段内跟踪疾病进展和可预测性 BC 将针对以下五个患者人群，包括代表性不足的种族/族裔群体。 目标：1) 提供已建立的血液生物标志物的测量，2) 开发和实施新型生物标志物 分析，3) 促进血液生物标志物与既定临床实践的整合，以推进转化 研究，4) 向国家阿尔茨海默病协调中心提供血液生物标志物数据，以及 5) 教育 培训医疗保健专业人员、科学家和学生使用生物标志物检测。 通过与 MADRC 临床核心、数据管理和统计部门密切合作来实现目标 核心、神经影像学核心、神经病理学核心和研究教育部分通过这些努力， BC 将显着加强 MADRC 支持的研究，从而带来持续和重大的成果 当我们对诊断和预测效用进行全面评估时，对该领域的影响 我们还将与其他 ADRC 和研究人员合作，帮助制定基于血液的生物标志物概况。 痴呆症评估和治疗的临床前景不断变化。